Literature DB >> 7705465

The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1.

S Perovic1, C Schleger, G Pergande, S Iskric, H Ushijima, P Rytik, W E Müller.   

Abstract

Flupirtine, a triaminopyridine derivative, is a non-opiate centrally acting analgesic agent with muscle relaxant properties. Now we show that this drug displays a potent cytoprotective effect on neurons (rat cortical cells) treated with (i) the excitatory amino acid N-methyl-D-aspartate (NMDA) or (ii) with the human immunodeficiency virus type 1 (HIV-1) coat protein gp120. In the absence of the drug the two agents cause a > 90% reduction of cell viability after a 18 h incubation. During this period the DNA in the cells undergoes fragmentation and shows a pattern which is typical for cell death. If the neurons were preincubated with flupirtine for 2 h and subsequently exposed to the cytotoxic agents an almost complete protection was achieved. The cytoprotective effect of flupirtine in vitro was significant (above 10 microM). Because flupirtine displays almost no clinical side effects and in light of the data presented here, flupirtine may be a promising drug also for the treatment of NMDA-mediated neurodegenerative disorders in general and for the treatment of AIDS-related encephalopathy in particular.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7705465     DOI: 10.1016/0922-4106(94)90006-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Flupirtine, a re-discovered drug, revisited.

Authors:  Istvan Szelenyi
Journal:  Inflamm Res       Date:  2013-01-16       Impact factor: 4.575

2.  Antiparkinsonian effect of flupirtine in monoamine-depleted rats.

Authors:  M Schwarz; M Nolden-Koch; J Purr; G Pergande; F Block
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Mumijo traditional medicine: fossil deposits from antarctica (chemical composition and beneficial bioactivity).

Authors:  Anna Aiello; Ernesto Fattorusso; Marialuisa Menna; Rocco Vitalone; Heinz C Schröder; Werner E G Müller
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-15       Impact factor: 2.629

4.  Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting.

Authors:  Nora Anderson; Juergen Borlak
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

5.  The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker.

Authors:  Tzu-Rong Su; Wen-Shan Zei; Ching-Chyuan Su; George Hsiao; Min-Jon Lin
Journal:  Evid Based Complement Alternat Med       Date:  2012-03-25       Impact factor: 2.629

6.  Rebalancing β-Amyloid-Induced Decrease of ATP Level by Amorphous Nano/Micro Polyphosphate: Suppression of the Neurotoxic Effect of Amyloid β-Protein Fragment 25-35.

Authors:  Werner E G Müller; Shunfeng Wang; Maximilian Ackermann; Meik Neufurth; Renate Steffen; Egherta Mecja; Rafael Muñoz-Espí; Qingling Feng; Heinz C Schröder; Xiaohong Wang
Journal:  Int J Mol Sci       Date:  2017-10-16       Impact factor: 5.923

7.  Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial.

Authors:  Jan Dörr; Klaus-Dieter Wernecke; Jens Würfel; Judith Bellmann-Strobl; Volker Siffrin; Muriel B Sättler; Mikael Simons; Andreas Linsa; Hayrettin Tumani; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-09       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.